Your browser doesn't support javascript.
loading
Reinfection by the SARS-CoV-2 P.1 variant in blood donors in Manaus, Brazil
Carlos A. Prete Jr.; Lewis F Buss; Renata Buccheri; Claudia M. M. Abrahim; Tassila Salomon; Myuki A. E. Crispim; Marcio K. Oikawa; Eduard Grebe; Allyson G. da Costa; Nelson A. Fraiji; Maria do P. S. S. Carvalho; Charles Whittaker; Neal Alexander; Nuno R. Faria; Christopher Dye; Vitor H. Nascimento; Michael Paul Busch; Ester C. Sabino.
Afiliação
  • Carlos A. Prete Jr.; Department of Electronic Systems Engineering, University of Sao Paulo
  • Lewis F Buss; Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
  • Renata Buccheri; Vitalant Research Institute, San Francisco CA, USA
  • Claudia M. M. Abrahim; Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil
  • Tassila Salomon; Fundacao Hemominas and Falculdade de Ciencias Medicas de Minas Gerais, Brazil
  • Myuki A. E. Crispim; Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
  • Marcio K. Oikawa; Center of Mathematics, Computing and Cognition, Universidade Federal do ABC, Brazil
  • Eduard Grebe; Vitalant Research Institute; University of California San Francisco, San Fracisco CA, USA; SACEMA, Stellenbosch University, Stellenbosch, South Africa
  • Allyson G. da Costa; Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
  • Nelson A. Fraiji; Fundacao Hospitalar de hematologia e Hemoterapia do Amazonas - HEMOAM
  • Maria do P. S. S. Carvalho; Fundacao Hospitalar de hematologia e Hemoterapia do Amazonas - HEMOAM
  • Charles Whittaker; Imperial College, London
  • Neal Alexander; London School of Hygiene and Tropical Medicine
  • Nuno R. Faria; Department of Infectious Disease Epidemiology, Imperial College London, UK; Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de Sao Paulo,
  • Christopher Dye; Department of Zoology, University of Oxford, UK
  • Vitor H. Nascimento; Department of Electronic Systems Engineering, University of Sao Paulo, Brazil
  • Michael Paul Busch; Vitalant Research Institute; University of California San Francisco, San Francisco CA, USA
  • Ester C. Sabino; Instituto de Medicina Tropical, University of Sao Paulo, Brazil
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21256644
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
BackgroundThe city of Manaus, north Brazil, was stricken by a second epidemic wave of SARS-CoV-2 despite high seroprevalence estimates, coinciding with the emergence of the Gamma (P.1) variant. Reinfections were postulated as a partial explanation for the second surge. However, accurate calculation of reinfection rates is difficult when stringent criteria as two time-separated RT-PCR tests and/or genome sequencing are required. To estimate the proportion of reinfections caused by the Gamma variant during the second wave in Manaus and the protection conferred by previous infection, we analyzed a cohort of repeat blood donors to identify anti-SARS-CoV-2 antibody boosting as a means to infer reinfection. MethodsWe tested serial blood samples from unvaccinated repeat blood donors in Manaus for the presence of anti-SARS-CoV-2 IgG antibody. Donors were required to have three or more donations and at least one donation during each epidemic wave. Donors were tested with two assays that display waning in early convalescence, enabling the detection of reinfection-induced boosting. The serial samples were used to divide donors into six groups defined based on the inferred sequence of infection and reinfection with non-Gamma and Gamma variants. ResultsFrom 3,655 repeat blood donors, 238 met all inclusion criteria, and 223 had enough residual sample volume to perform both serological assays. Using a strict serological definition of reinfection, we found 13.6% (95% CI 7.0% - 24.5%) of all presumed Gamma infections that were observed in 2021 were reinfections. If we also include cases of probable or possible reinfections, these percentages increase respectively to 22.7% (95% CI 14.3% - 34.2%) and 39.3% (95% CI 29.5% - 50.0%). Previous infection conferred a protection against reinfection of 85.3% (95% CI 71.3% - 92.7%), decreasing to respectively 72.5% (95% CI 54.7% - 83.6%) and 39.5% (95% CI 14.1% - 57.8%) if probable and possible reinfections are included. ConclusionsReinfection due to Gamma is common and may play a significant role in epidemics where Gamma is prevalent, highlighting the continued threat variants of concern pose even to settings previously hit by substantial epidemics.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint